Ono Mayumi
Department of Pharmaceutical Oncology, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka 812-8582, Japan.
Cancer Sci. 2008 Aug;99(8):1501-6. doi: 10.1111/j.1349-7006.2008.00853.x.
Both inflammation and angiogenesis are exacerbated by increased production of chemokines/cytokines, growth factors, proteolytic enzymes, proteoglycans, lipid mediators and prostaglandins. It has been reported that approximately 15-20% of all malignancies are initiated or exacerbated by inflammation. Initiation and progression of cancer are also closely linked to angiogenesis. Infiltration of macrophages is a dramatic and common feature of inflammation, angiogenesis and cancer, and has been recently highlighted in an attempt to develop novel strategies for treating cancer. The recruitment and infiltration of macrophages in the tumor microenvironment activates them to support the malignant progression of cancer cells, and these macrophages are called tumor-associated macrophages. In a model of experimental angiogenesis using mouse corneas, macrophages infiltrated tissue in response to inflammatory cytokines and produced chemokines and angiogenesis-promoting factors, such as vascular endothelial growth factor-A, interleukin-8, matrix metalloproteinases, prostanoids and reactive oxygen species. Moreover, in a cancer xenograft model, inflammatory stimuli by a representative inflammatory cytokine, interleukin-1beta, enhanced tumor growth and angiogenesis with infiltration and activation of macrophages. Co-culture of cancer cells with macrophages synergistically stimulated production of various angiogenesis-related factors when stimulated by the inflammatory cytokine. This inflammatory angiogenesis in both mouse cornea and a tumor model was mediated, in part, by activation of nuclear factor kappaB and activator protein 1 (Jun/Fos). Administration of either nuclear factor kappaB-targeting drugs or cyclooxygenase 2 inhibitors or depletion of macrophages could block both inflammatory angiogenesis and tumor angiogenesis. Thus, both inflammatory and angiogenic responses in tumor stroma could be targets for development of anticancer therapeutic drugs.
趋化因子/细胞因子、生长因子、蛋白水解酶、蛋白聚糖、脂质介质和前列腺素产量的增加会加剧炎症和血管生成。据报道,所有恶性肿瘤中约15 - 20%是由炎症引发或加剧的。癌症的起始和进展也与血管生成密切相关。巨噬细胞的浸润是炎症、血管生成和癌症的一个显著且常见的特征,最近在开发新型癌症治疗策略的尝试中受到了关注。肿瘤微环境中巨噬细胞的募集和浸润会激活它们以支持癌细胞的恶性进展,这些巨噬细胞被称为肿瘤相关巨噬细胞。在使用小鼠角膜的实验性血管生成模型中,巨噬细胞响应炎性细胞因子浸润组织,并产生趋化因子和促进血管生成的因子,如血管内皮生长因子 - A、白细胞介素 - 8、基质金属蛋白酶、类前列腺素和活性氧。此外,在癌症异种移植模型中,代表性炎性细胞因子白细胞介素 - 1β引起的炎性刺激通过巨噬细胞的浸润和激活增强了肿瘤生长和血管生成。当受到炎性细胞因子刺激时,癌细胞与巨噬细胞共培养会协同刺激各种血管生成相关因子的产生。小鼠角膜和肿瘤模型中的这种炎性血管生成部分是由核因子κB和激活蛋白1(Jun/Fos)的激活介导的。给予核因子κB靶向药物、环氧化酶2抑制剂或清除巨噬细胞均可阻断炎性血管生成和肿瘤血管生成。因此,肿瘤基质中的炎性和血管生成反应都可能成为抗癌治疗药物开发的靶点。